ArticleAmerican journal of physiology. Gastrointestinal and liver physiology2015
Activation of the GP130-STAT3 axis and its potential implications in nonalcoholic fatty liver disease.
Article in American journal of physiology. Gastrointestinal and liver physiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Interleukin-6 gene polymorphisms and susceptibility to liver diseases: A meta-analysis.Medicine · 2019Pooled it
- Mechanism of arbutin in metabolic dysfunction-associated fatty liver disease based on multi-omics research.Bioresources and bioprocessing · 2026Article
- Non-linear relationship between triglyceride glucose index and new-onset diabetes among individuals with non-alcoholic fatty liver disease: a cohort study.Lipids in health and disease · 2025Article
- Carabrone Attenuates Metabolic Dysfunction-Associated Steatohepatitis by Targeting STAT3 in Mice.MedComm · 2025Article
- The gp130/STAT3-endoplasmic reticulum stress axis regulates hepatocyte necroptosis in acute liver injury.Croatian medical journal · 2023Article
- Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link.World journal of gastroenterology · 2022Review
- Steatosis, Steatohepatitis and Cancer Immunotherapy: An Intricate Story.International journal of molecular sciences · 2021Review
- Myeloid-Cell-Specific IL-6 Signaling Promotes MicroRNA-223-Enriched Exosome Production to Attenuate NAFLD-Associated Fibrosis.Hepatology (Baltimore, Md.) · 2021Observational
- Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.Pharmacological reviews · 2020Review
- Maternal High-Fat Diet Leads to Non-alcoholic Fatty Liver Disease Through Upregulating HepaticFrontiers in nutrition · 2020Article
- Molecular links between non-alcoholic fatty liver disease and hepatocellular carcinoma.Hepatoma research · 2019Article
- Mitochondrial Dysfunction in the Transition from NASH to HCC.Metabolites · 2019Review
- GVS-12 attenuates non-alcoholic steatohepatitis by suppressing inflammatory responsesRSC advances · 2019Article
- Elevated free fatty acid level is associated with insulin-resistant state in nondiabetic Chinese people.Diabetes, metabolic syndrome and obesity : targets and therapy · 2019Article
- Possible association of arrestin domain-containing protein 3 and progression of non-alcoholic fatty liver disease.International journal of medical sciences · 2019Article
- Metastasis-associated lung adenocarcinoma transcript 1 as a common molecular driver in the pathogenesis of nonalcoholic steatohepatitis and chronic immune-mediated liver damage.Hepatology communications · 2018Article
- Identification of key genes in non‑alcoholic fatty liver disease progression based on bioinformatics analysis.Molecular medicine reports · 2018Article
- Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma.Canadian journal of gastroenterology & hepatology · 2018Review
- Upregulation of non-canonical Wnt ligands and oxidative glucose metabolism in NASH induced by methionine-choline deficient diet.Trends in cell & molecular biology · 2018Article
- Increased Expression of Resistin in MicroRNA-155-Deficient White Adipose Tissues May Be a Possible Driver of Metabolically Healthy Obesity Transition to Classical Obesity.Frontiers in physiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
Abstract
The status of the GP130-STAT3 signaling pathway in humans with nonalcoholic fatty liver disease (NAFLD) and its relevance to disease pathogenesis are unknown. The expression of the gp130-STAT3 axis and gp130 cytokine receptors were studied in subjects with varying phenotypes of NAFLD including nonalcoholic steatohepatitis (NASH) and compared with lean and weight-matched controls without NAFLD. Gp130 and its downstream signaling element (Tyk2 and STAT3) expression were inhibited in obese controls whereas they were increased in NAFLD. IL-6 levels were increased in NASH and correlated with gp130 expression (P < 0.01). Palmitate inhibited gp130-STAT3 expression and signaling. IL-6 and palmitate inhibited hepatic insulin signaling via STAT3-dependent and independent mechanisms, respectively. STAT3 overexpression reversed palmitate-induced lipotoxicity by increasing autophagy (ATG7) and decreasing endoplasmic reticulum stress. These data demonstrate that the STAT3 pathway is activated in NAFLD and can worsen insulin resistance while protecting against other lipotoxic mechanisms of disease pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.